National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 5) (No. PB 31 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L00842

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 31 of 2013
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 5)
 
National Health Act 1953
___________________________________________________________________________
 
I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 21 May 2013
 
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Principal Pharmacy Advisor
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No.5).
 
(2)                This Instrument may also be cited as PB 31 of 2013.
 
2             Commencement
                This Instrument commences on 1 June 2013.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]    Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 150 mg in 15 mL with manner of administration Injection and brand Carboplatin Ebewe:
substitute:
 
Solution for I.V. injection 150 mg in 15 mL
Injection
Carbaccord
 
Carboplatin Ebewe
WQ
 
SZ
MP
 
MP
 
D
 
D
 
 
[2]    Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 450 mg in 45 mL with manner of administration Injection and brand Carboplatin Ebewe:
substitute:
 
Solution for I.V. injection 450 mg in 45 mL
Injection
Carbaccord
 
Carboplatin Ebewe
WQ
 
SZ
MP
 
MP
 
D
 
D
[3]    Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 50 mg in 5 mL with manner of administration Injection and brand Carboplatin Ebewe:
substitute:
 
Solution for I.V. injection 50 mg in 5 mL
Injection
Carbaccord
 
Carboplatin Ebewe
WQ
 
SZ
MP
 
MP
 
D
 
D
 
 
[4]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection and brand Gemcitabine Actavis:
omit from the column headed “Responsible Person” : TA
substitute: WQ
 
[5]    Schedule 1 Part 1, after the entry for Gemcitabine in the form Powder for I.V infusion 2 g (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for injection:
insert:
 
Gemcitabine Actavis 2000 
WQ
MP
 
D
 
[6]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection and brand Gemcitabine Actavis:
omit from the column headed “Responsible Person” : TA
substitute: WQ
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.comlaw.gov.au.